Dr. Scott Gottlieb stressed the importance of vaccinating as many people as possible and warned of the potentially dire spring and summer months without protection from the new coronavirus. Around the world
“If we are unable to get more defensive immunity in the population, we may be facing a situation where we are forever infected in the spring and summer as these strains have a foothold here,” said the former FDA chief. In the Trump administration in an interview on CNBC̵7;s “The News with Shepard Smith” Thursday evening.
Ohio researchers have found a new strain of COVID in the United States with mutations that scientists have never seen before. They also revealed that they found another species similar to the highly inherited breed from the UK. The researchers said that these mutations “More likely to infect the virus”
Gottlieb cautions that these breeds can turn what might have been a relatively quiet spring and summer into. “Summers we have more infections as these strains are spreading and spread more easily, even in warmer months when we shouldn’t have had a large number of coronavirus transmission.”
Long-time Harvard professor Dr David Edwards echoed Gottlieb’s sentiment about the timing and importance of the introduction of an effective vaccine.
“Of course, time is important when confronted with any living organism,” said FEND founder Edwards, a nasal cleansing spray developed for the coronavirus outbreak. “Our main goal this winter is to vaccinate as many people as possible with the effective vaccines that we currently have.”
The U.S. has distributed 30.6 million vaccines and placed 11 million in their arms, according to the Centers for Disease Control and Prevention. However, all forecasts compiled by the CDC estimate that another 92,000 Americans will die from COVID in the next three weeks.
The United States has killed 8,400 in the past two days and nearly 40,000 in less than two weeks of 2021, according to CNBC’s analysis of Johns Hopkins data.On average, the outbreak kills Americans. More than 3,300 people per day
Gottlieb told host Shepard Smith he was “encouraged” by Johnson & Johnson’s one-dose vaccine and “confident” in the company’s ability to scale production to help bolster the rollout of the Covid vaccine across the US.
“The early data was interesting,” Gottlieb said. “One of the things we see in the data is that the antibody response continues to produce after about two and a half months.”
Disclosure: Scott Gottlieb is a CNBC contributor and board member of Pfizer, genetic testing startup Tempus, and biotech company Illumina. Pfizer has a production agreement with Gilead As for remdesivir Gottlieb is also co-chair of the Norwegian Cruise Line Holdings‘and Royal Caribbean“Healthy Sail Panel”